Analyst: Novo is down-prioritizing Europe
According to Sydbank analyst, Søren Løntoft Hansen, Novo Nordisk has purposely set a high price on the drug Tresiba in Europe in order to gain even higher prices on growth markets.
by Stefan Singh Kailay
“It is the overall assessment of the IRF that there have been shown no clear clinical advantages from the use of degludec over NPH-insulin, glargin or detemir which might outweigh the significantly higher treatment price.”
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
